(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.02% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.22%.
Bioventus's revenue in 2026 is $581,848,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $51,319,592,526, with the lowest BVS revenue forecast at $49,611,686,444, and the highest BVS revenue forecast at $53,490,003,949. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,889,292,832, with the lowest BVS revenue forecast at $52,824,837,178, and the highest BVS revenue forecast at $57,922,486,944.
In 2028, BVS is forecast to generate $58,272,309,165 in revenue, with the lowest revenue forecast at $56,409,674,023 and the highest revenue forecast at $60,720,223,792.